QiShenYiQi pill attenuates atherosclerosis by promoting regulatory T cells, inhibiting T helper 17 cells and accelerating cholesterol excretion

Objective The aim of this study was to explore potential immunoregulatory mechanisms underlying the suppressive effect on atherosclerosis of QiShenYiQi pill (QSYQ). Methods and Results Male ApoE-/- mice were maintained on a Western-type diet and QSYQ treatment for eight weeks. Determination of atherosclerosis demonstrated that QSYQ attenuated plaque formation and decreased the level of blood low-density lipoproteins-cholesterol. QSYQ treatment did not affect body weight but reduced the ratio of liver weight and body weight. Western blots of liver showed that QSYQ increased the expression of liver X receptor alpha and ATP-binding cassette sub-family G member 5. Western blots of atherosclerotic aorta revealed that QSYQ inhibited the expression of cluster of differentiation 36, promoted the expression of forkhead box P3 and decreased interleukin-17A expression. Western blots of spleen showed that QSYQ decreased the expression of mothers against decapentaplegic homolog 2/3 and forkhead box P3, as well as attenuated the expression of spleen interleukin-6, RAR-related orphan receptor gamma and interleukin-17A. Conclusions QSYQ exerted an anti-atherosclerosis effect by promoting regulatory T cells in atherosclerotic lesion, inhibiting T helper 17 cells in plaque and spleen and accelerating liver cholesterol excretion.

• Publication year

  2017

• Venue

  OncoTarget

• Publication date

  2017-07-07

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.18632/oncotarget.19072PMID 29137256PMCID 5669882
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pillars Article: Control of Regulatory T Cell Development by the Transcription Factor Foxp3. Science 2003. 299: 1057-1061.

  2017cited by this paper
• Astragaloside IV attenuates inflammatory reaction via activating immune function of regulatory T-cells inhibited by HMGB1 in mice

  2016cited by this paper
• CCR5+T-bet+FoxP3+ Effector CD4 T Cells Drive Atherosclerosis.

  2016cited by this paper
• QiShenYiQi Attenuates Renal Interstitial Fibrosis by Blocking the Activation of β-Catenin

  2016cited by this paper
• Cardioprotection against ischemia/reperfusion injury by QiShenYiQi Pill® via ameliorate of multiple mitochondrial dysfunctions

  2015cited by this paper
• Qishenyiqi Dropping Pill attenuates myocardial fibrosis in rats by inhibiting RAAS-mediated arachidonic acid inflammation.

  2015cited by this paper
• QiShenYiQi Pills, a compound in Chinese medicine, protects against pressure overload-induced cardiac hypertrophy through a multi-component and multi-target mode

  2015cited by this paper
• Treg/Th17 balance in stable CAD patients with different stages of coronary atherosclerosis.

  2015cited by this paper
• Proatherogenic conditions promote autoimmune T helper 17 cell responses in vivo.

  2014cited by this paper
• Qishenyiqi Protects Ligation-Induced Left Ventricular Remodeling by Attenuating Inflammation and Fibrosis via STAT3 and NF-κB Signaling Pathway

  2014cited by this paper
• CD36-Dependent 7-Ketocholesterol Accumulation in Macrophages Mediates Progression of Atherosclerosis in Response to Chronic Air Pollution Exposure

  2014cited by this paper
• Astragaloside IV inhibits platelet-derived growth factor-BB-stimulated proliferation and migration of vascular smooth muscle cells via the inhibition of p38 MAPK signaling

  2014cited by this paper
• Regression of atherosclerosis with anti-CD3 antibody via augmenting a regulatory T-cell response in mice.

  2014cited by this paper
• QiShenYiQi Pills® prevent cardiac ischemia-reperfusion injury via energy modulation.

  2013cited by this paper
• CD4+CD25+Foxp3+ T cells contribute to the antiasthmatic effects of Astragalus membranaceus extract in a rat model of asthma.

  2013cited by this paper
• Depletion of FOXP3+ regulatory T cells promotes hypercholesterolemia and atherosclerosis.

  2013cited by this paper
• Immune effector mechanisms implicated in atherosclerosis: from mice to humans.

  2013cited by this paper
• Cardioprotective Effects of Qishenyiqi Mediated by Angiotensin II Type 1 Receptor Blockade and Enhancing Angiotensin-Converting Enzyme 2

  2012cited by this paper
• Cytokine Therapy With Interleukin-2/Anti–Interleukin-2 Monoclonal Antibody Complexes Expands CD4+CD25+Foxp3+ Regulatory T Cells and Attenuates Development and Progression of Atherosclerosis

  2012cited by this paper
• The IL-17A/IL-17RA Axis Plays a Proatherogenic Role via the Regulation of Aortic Myeloid Cell Recruitment

  2012cited by this paper
• Effector Memory T cells Are Associated With Atherosclerosis in Humans and Animal Models

  2012cited by this paper
• The immune system in atherosclerosis

  2011cited by this paper
• Global Chemome Study by LC Coupled with DAD and ESI–Q–TOF MS of a Composite Traditional Chinese Medicine Qishenyiqi Dropping Pills

  2010cited by this paper
• A Critical Function of Th17 Proinflammatory Cells in the Development of Atherosclerotic Plaque in Mice

  2010cited by this paper
• The "atheroprotective" mediators apolipoprotein A-I and Foxp3 are over-abundant in unstable carotid plaques.

  2010cited by this paper
• Blockade of Interleukin-17A Results in Reduced Atherosclerosis in Apolipoprotein E–Deficient Mice

  2010cited by this paper
• Mechanisms of foxp3+ T regulatory cell-mediated suppression.

  2009cited by this paper
• The Th17/Treg imbalance in patients with acute coronary syndrome.

  2008cited by this paper
• CD36 modulates migration of mouse and human macrophages in response to oxidized LDL and may contribute to macrophage trapping in the arterial intima.

  2008influential reference
• Low Numbers of FOXP3 Positive Regulatory T Cells Are Present in all Developmental Stages of Human Atherosclerotic Lesions

  2007cited by this paper
• The immune response in atherosclerosis: a double-edged sword

  2006cited by this paper
• Adoptive Transfer of CD4+ T Cells Reactive to Modified Low-Density Lipoprotein Aggravates Atherosclerosis

  2006cited by this paper
• Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

  2006cited by this paper
• A CD36‐dependent signaling cascade is necessary for macrophage foam cell formation

  2006influential reference
• Non‐physiological overexpression of the low density lipoprotein receptor (LDLr) gene in the liver induces pathological intracellular lipid and cholesterol storage

  2004cited by this paper
• Toll-like receptors in the pathogenesis of human disease

  2004cited by this paper
• Supporting Online Material

  2003cited by this paper
• The liver X receptor gene team: Potential new players in atherosclerosis

  2002influential reference
• Atherosclerosis--an inflammatory disease.

  1999cited by this paper
• Guide for the Care and Use of Laboratory Animals

  1996cited by this paper

• Effects of Chinese Medicine on modulating interleukin-17-regulated macrophages in coronary heart disease

  2025cites this paper
• QiShenYiQi pill inhibits atherosclerosis by promoting reverse cholesterol transport PPARγ-LXRα/β-ABCA1 pathway.

  2023cites this paper
• QiShenYiQi pill inhibits atherosclerosis by promoting TTC39B-LXR mediated reverse cholesterol transport in liver.

  2023cites this paper
• Interleukin 17, the double-edged sword in atherosclerosis.

  2022cites this paper
• Synergy of "Yiqi" and "Huoxue" components of QishenYiqi formula in Ischemic stroke protection via lysosomal/inflammatory mechanisms.

  2022cites this paper
• Recent advances of traditional Chinese medicine for the prevention and treatment of atherosclerosis.

  2022cites this paper
• Atheroprotective Effects and Mechanisms of Postmarketing Chinese Patent Formulas in Atherosclerosis Models: A Systematic Review

  2021influential citation
• Bushenkangshuai Tablet Reduces Atherosclerotic Lesion by Improving Blood Lipids Metabolism and Inhibiting Inflammatory Response via TLR4 and NF-κB Signaling Pathway

  2018cites this paper
• The Signaling Pathways Involved in the Antiatherosclerotic Effects Produced by Chinese Herbal Medicines

  2018cites this paper